| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
|
Nat Med
|
2003
|
7.78
|
|
2
|
Shifting foci of hematopoiesis during reconstitution from single stem cells.
|
Proc Natl Acad Sci U S A
|
2003
|
4.41
|
|
3
|
Protective conditioning for acute graft-versus-host disease.
|
N Engl J Med
|
2005
|
4.07
|
|
4
|
Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production.
|
Blood
|
2006
|
3.33
|
|
5
|
Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells.
|
Blood
|
2007
|
3.27
|
|
6
|
In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets.
|
Blood
|
2005
|
3.13
|
|
7
|
Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD.
|
Blood
|
2004
|
2.95
|
|
8
|
Hematopoietic stem and progenitor cells: clinical and preclinical regeneration of the hematolymphoid system.
|
Annu Rev Med
|
2005
|
2.92
|
|
9
|
Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging.
|
Blood
|
2002
|
2.79
|
|
10
|
Synergistic antitumor effects of immune cell-viral biotherapy.
|
Science
|
2006
|
2.37
|
|
11
|
Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells.
|
Cell Stem Cell
|
2011
|
2.35
|
|
12
|
Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells.
|
Blood
|
2003
|
2.27
|
|
13
|
Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity.
|
Blood
|
2007
|
2.19
|
|
14
|
Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2005
|
2.12
|
|
15
|
Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation.
|
Blood
|
2003
|
2.08
|
|
16
|
Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation.
|
Proc Natl Acad Sci U S A
|
2009
|
2.02
|
|
17
|
Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
1.96
|
|
18
|
In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation.
|
Blood
|
2006
|
1.89
|
|
19
|
TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors.
|
Blood
|
2009
|
1.89
|
|
20
|
Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation.
|
Transplantation
|
2005
|
1.82
|
|
21
|
In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity.
|
Blood
|
2008
|
1.67
|
|
22
|
A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma.
|
Biol Blood Marrow Transplant
|
2005
|
1.60
|
|
23
|
The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation.
|
Blood
|
2007
|
1.57
|
|
24
|
Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.
|
Blood
|
2003
|
1.55
|
|
25
|
NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects.
|
Blood
|
2010
|
1.49
|
|
26
|
Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells.
|
Biol Blood Marrow Transplant
|
2011
|
1.49
|
|
27
|
Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs.
|
Blood
|
2007
|
1.48
|
|
28
|
Mast cells suppress murine GVHD in a mechanism independent of CD4+CD25+ regulatory T cells.
|
Blood
|
2013
|
1.47
|
|
29
|
Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells.
|
Blood
|
2011
|
1.44
|
|
30
|
Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells.
|
Blood
|
2012
|
1.43
|
|
31
|
Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells.
|
J Immunol
|
2005
|
1.35
|
|
32
|
Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation.
|
J Immunol
|
2008
|
1.34
|
|
33
|
Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen.
|
Blood
|
2008
|
1.33
|
|
34
|
Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease.
|
Blood
|
2006
|
1.31
|
|
35
|
Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence.
|
Blood
|
2012
|
1.31
|
|
36
|
Role of naturally arising regulatory T cells in hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2006
|
1.29
|
|
37
|
Evaluation of effector cell fate and function by in vivo bioluminescence imaging.
|
Methods
|
2003
|
1.25
|
|
38
|
Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
|
Clin Cancer Res
|
2006
|
1.20
|
|
39
|
Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells.
|
Int J Cancer
|
2009
|
1.19
|
|
40
|
Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy.
|
Cell Cycle
|
2007
|
1.15
|
|
41
|
Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism.
|
Blood
|
2011
|
1.11
|
|
42
|
Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia.
|
Biol Blood Marrow Transplant
|
2005
|
1.10
|
|
43
|
Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
|
Biol Blood Marrow Transplant
|
2010
|
1.10
|
|
44
|
The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia.
|
Blood
|
2006
|
1.08
|
|
45
|
Understanding immune cell trafficking patterns via in vivo bioluminescence imaging.
|
J Cell Biochem Suppl
|
2002
|
1.07
|
|
46
|
Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation.
|
Blood
|
2013
|
1.07
|
|
47
|
Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma.
|
J Clin Oncol
|
2009
|
1.04
|
|
48
|
Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose.
|
Blood
|
2004
|
1.02
|
|
49
|
Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
|
Cancer Res
|
2002
|
1.02
|
|
50
|
CD101 surface expression discriminates potency among murine FoxP3+ regulatory T cells.
|
J Immunol
|
2007
|
1.02
|
|
51
|
Tissue-specific homing and expansion of donor NK cells in allogeneic bone marrow transplantation.
|
J Immunol
|
2009
|
1.01
|
|
52
|
CD8+CD44(hi) but not CD4+CD44(hi) memory T cells mediate potent graft antilymphoma activity without GVHD.
|
Blood
|
2011
|
1.01
|
|
53
|
Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience.
|
Biol Blood Marrow Transplant
|
2008
|
1.01
|
|
54
|
Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow.
|
Blood
|
2012
|
0.99
|
|
55
|
Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells.
|
Clin Cancer Res
|
2005
|
0.96
|
|
56
|
Cytomegalovirus viral load and virus-specific immune reconstitution after peripheral blood stem cell versus bone marrow transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
0.95
|
|
57
|
Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice.
|
J Clin Immunol
|
2002
|
0.94
|
|
58
|
Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses.
|
Biol Blood Marrow Transplant
|
2009
|
0.94
|
|
59
|
Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells.
|
Cancer Res
|
2010
|
0.93
|
|
60
|
Regulation of different inflammatory diseases by impacting the mevalonate pathway.
|
Immunology
|
2009
|
0.93
|
|
61
|
A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease.
|
Blood
|
2013
|
0.93
|
|
62
|
High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
|
Biol Blood Marrow Transplant
|
2006
|
0.93
|
|
63
|
Biology and clinical effects of natural killer cells in allogeneic transplantation.
|
Curr Opin Oncol
|
2010
|
0.92
|
|
64
|
CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies.
|
Exp Hematol
|
2005
|
0.91
|
|
65
|
Host-derived interleukin-18 differentially impacts regulatory and conventional T cell expansion during acute graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2007
|
0.91
|
|
66
|
CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells.
|
Cancer Res
|
2010
|
0.90
|
|
67
|
Multi-modality imaging identifies key times for annexin V imaging as an early predictor of therapeutic outcome.
|
Mol Imaging
|
2004
|
0.89
|
|
68
|
Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma.
|
Biol Blood Marrow Transplant
|
2010
|
0.86
|
|
69
|
Ex vivo expanded dendritic cells home to T-cell zones of lymphoid organs and survive in vivo after allogeneic bone marrow transplantation.
|
Am J Pathol
|
2005
|
0.86
|
|
70
|
Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment.
|
Blood
|
2014
|
0.85
|
|
71
|
A novel technique for the enrichment of primary ovarian cancer cells.
|
Am J Obstet Gynecol
|
2007
|
0.85
|
|
72
|
Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts.
|
Biol Blood Marrow Transplant
|
2009
|
0.84
|
|
73
|
Cancer vaccines and T cell therapy.
|
Biol Blood Marrow Transplant
|
2012
|
0.83
|
|
74
|
A diagnostic window for the treatment of acute graft-versus-host disease prior to visible clinical symptoms in a murine model.
|
BMC Med
|
2013
|
0.83
|
|
75
|
Treatment of 4T1 metastatic breast cancer with combined hypofractionated irradiation and autologous T-cell infusion.
|
Radiat Res
|
2014
|
0.82
|
|
76
|
Natural and expanded CD4(+)CD25(+) regulatory T cells in bone marrow transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
0.82
|
|
77
|
Plasmacytoid dendritic cells take up opsonized antigen leading to CD4+ and CD8+ T cell activation in vivo.
|
J Immunol
|
2008
|
0.81
|
|
78
|
Mapping immune processes in intact tissues at cellular resolution.
|
J Clin Invest
|
2012
|
0.80
|
|
79
|
Acute graft-versus-host disease-challenge for a broader application of allogeneic hematopoietic cell transplantation.
|
Curr Stem Cell Res Ther
|
2006
|
0.79
|
|
80
|
IL-17 gene ablation does not impact Treg-mediated suppression of graft-versus-host disease after bone marrow transplantation.
|
Biol Blood Marrow Transplant
|
2013
|
0.78
|
|
81
|
Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity.
|
Proc Natl Acad Sci U S A
|
2012
|
0.78
|
|
82
|
Methods for imaging cell fates in hematopoiesis.
|
Methods Mol Med
|
2007
|
0.78
|
|
83
|
A killer choice for cancer immunotherapy.
|
Immunol Res
|
2014
|
0.77
|
|
84
|
Engraftment of embryonic stem cells and differentiated progeny by host conditioning with total lymphoid irradiation and regulatory T cells.
|
Cell Rep
|
2015
|
0.76
|
|
85
|
A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cells.
|
Blood
|
2013
|
0.76
|
|
86
|
Immune regulatory networks in the post-transplant setting.
|
Blood Cells Mol Dis
|
2007
|
0.75
|